部份中文紫杉醇处方资料（仅供参考）
英文名：paclitaxel
商品名：Genexol-PM
中文名：胶束化紫杉醇干粉注射剂
生产商：Samyang Biopharm
药品简介
新型纳米抗肿瘤药—胶束化紫杉醇,为一种新型放射增敏剂的非小细胞肺癌、乳腺癌、卵巢癌治疗特效药
适应症：
该药物可单独或组合使用以治疗卵巢癌或乳腺癌或肺癌。
1）卵巢癌
（1）与其他化疗药物联合用作一线治疗
（2）用作治疗标准治疗失败的转移性卵巢癌的二线治疗
2）乳腺癌
（1）作为治疗标准疗法失败的转移性乳腺癌的二线疗法
（2）结节性阳性乳腺癌的辅助治疗：含标准阿霉素的联合化疗后使用
（3）HER2（人类表皮生长因子受体2蛋白）过表达（IHC 3+或FISH阳性），并与曲妥珠单抗联合用于尚未接受化疗的转移性乳腺癌。
3）肺癌：用作晚期非小细胞肺癌的一线治疗
4）胃癌：晚期和转移性或局部复发性胃癌
用法与用量：
为防止出现严重的超敏反应，应在给予此药物之前对所有患者进行治疗。预处理应通过在服药THIS DRUG前30至60分钟口服地塞米松20mg（或同等剂量），或在THIS DRUG用药30至60分钟内静脉注射苯海拉明50mg（或同等疗法）。可以在给药前30至60分钟与西咪替丁（300mg）或雷尼替丁（50mg）静脉内给药。
1）卵巢癌
（1）当用作卵巢癌治疗的一线治疗时，每3周每3周滴入175mg/m²的THIS DRUG，然后滴加75mg/m²的顺铂。
（2）在标准治疗失败的转移性卵巢癌患者中，每3周每3小时给予175mg/m2的THIS DRUG滴注。
2）乳腺癌
（1）标准治疗失败的乳腺癌患者每3周应在3个小时内滴入175mg/m2的THIS DRUG。
（2）作为结节阳性乳腺癌的辅助治疗，在含阿霉素的联合化疗后，每3周分4疗程滴注175mg/m2的THIS DRUG。
（3）当与曲妥珠单抗联合治疗从未曾用化学疗法治疗过的HER2过表达转移性乳腺癌时，紫杉醇175mg/m2每3周滴注3小时。如果先前给予的曲妥珠单抗的耐受性良好，则可以在首次给予曲妥珠单抗的次日开始紫杉醇的给药，也可以在曲妥珠单抗给药后立即开始紫杉醇的给药。
曲妥珠单抗的初始剂量是在90分钟内滴注每千克体重4毫克，然后从下周开始每周给药每千克体重2毫克。
3）肺癌
当用作治疗晚期非小细胞肺癌的一线疗法时，每3周静脉给予175mg/m2的THIS DRUG，每3周静脉注射一次，然后再给予80mg/m2的顺铂。
4）胃癌
患有晚期和转移性或局部复发性胃癌的患者应在3小时内接受175-210mg/m2的滴注方法，并至少休息3周。设定为1个周期，并重复给药。根据年龄和症状适当减少剂量。除非中性粒细胞计数至少为1,500个细胞/ mm3，血小板计数至少为100,000个细胞/mm3，否则不应重复此疗程。对于在此药物治疗期间发生严重中性粒细胞减少症（中性粒细胞计数<500细胞/ mm3超过7天）或严重周围神经病变的患者，在下一个此药物疗程中应将剂量降低20％。
静脉溶液的制备
滴注前应稀释此药。用0.9％氯化钠注射液或5％葡萄糖注射液，5％葡萄糖/0.9%氯化钠注射液和5％葡萄糖林格溶液稀释该药物，使紫杉醇的最终浓度为0.3〜1.2mg/ml。该溶液在室温（15〜30oC）下物理化学稳定27小时。在溶液制备过程中溶液可能变浑浊，但这是由于赋形剂引起的。通过在线中装有过滤器（0.22微米）的静脉输液管进行静脉模拟的结果是，确认没有明显的滴度损失。
-------------------------------------------------------- 
Genexol® PM Inj.
Samyang biopharmaceuticals provides wide range of injections which includes genexol® pm inj. It is a patented new formulation of paclitaxel. The new formulation is free from toxic surfactant and allows significantly higher dosing of paclitaxel to the patients. Indication: it's a first line treatm...
Samyang biopharmaceuticals provides wide range of injections which includes genexol® pm inj. It is a patented new formulation of paclitaxel. The new formulation is free from toxic surfactant and allows significantly higher dosing of paclitaxel to the patients.
Indication:
it's a first line treatment for breast cancer, lung cancer, ovarian cancer.
Dosage: is administered at a dose of 300mg/m2 intravenously over 3 hours every 3weeks; it is administered over 3hours intravenously according to the dose below, followed by cisplatin at a dose of 60mg/m2 intravenously; it is administered at a dose of 260mg/m2 intravenously over 3hours every 3weeks. Packaging: 30mg /vial , 100mg /vial.
---------------------------------------------
Breast Cancer, Lung cancer, Pancreatic caner(cytotoxic chemotheraphy)
Genexol-PM is a polymeric micelle formulated paclitaxel, free of Cremophor EL. Objectives with Genexol-PM are to reduce Cremophor EL-related toxicities and to increase therapeutic efficacy. Polymeric micelles are composed of hundreds of amphiphilic diblock copolymers. Block copolymers include poly-(ethylene glycol) used as nonimmunogenic carriers and biodegradable core-forming poly-(D,L-lactic acid) to solubilize hydrophobic drug. Genexol-PM showed 3-times higher maximum tolerated dose in mice vs. Taxol.
Genexol-PM (vs. Taxol) showed 2-3-fold higher levels of paclitaxel in tissues including liver, spleen, kidney, lung, and tumors. In vivo antitumor efficacy of Genexol-PM was significantly higher than Taxol. Based on results from Phase I and II trials in Korea/US, the therapeutic dose recommended is 300mg/m2, much higher than Taxol (175 mg/m2). With favorable results from Phase II studies - Breast/Lung Cancer, Genexol-PM obtained a pre-market approval in Korea in July 2006. A phase IIa pancreatic cancer trial is on-going in US.